SecBot SecBot
Biotech Drug Report Generated Oct 26, 2026

mocertatug rezetecan

GSK·GSK plc
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 3
Time to market
Unknown; Phase 3 trials began enrolling in 2026. If successful, potential regulatory filings would be at least 2-4 years away (2028-2030).
Why 4/10
No hard dated catalyst (PDUFA, pivotal readout) is scheduled in the next ~12 months, the five Phase 3 trials began enrolling in 2026 and pivotal readouts are likely 2-3+ years away. GSK is a large-cap diversified pharma, so this single early-stage asset drives a small fraction of the stock's value.
Actionable Insight NEUTRAL

GSK just presented updated BEHOLD-1 Phase 1b data at ESMO 2026 (Oct 23-27) showing a 62% confirmed ORR at the 5.8 mg/kg Phase 3 dose in platinum-resistant ovarian cancer. The next catalysts are Phase 3 interim/final readouts from the five pivotal trials (BEHOLD-Ovarian01, BEHOLD-Endometrial01, etc.) that began enrolling in 2026, those readouts are likely 2-3+ years away. For a large-cap pharma like GSK, this is one of many pipeline assets and not a near-term binary event.

Price Chart

Loading chart...

Executive Summary

Mocertatug rezetecan (Mo-Rez, GSK5733584, HS-20089) is an investigational B7-H4-targeted antibody-drug conjugate (ADC) being developed by GSK plc for gynecologic cancers. It was licensed from Hansoh Pharma in October 2023 for $85M upfront. Updated Phase 1b BEHOLD-1 data presented at ESMO 2026 (this week) showed a 62% confirmed objective response rate at the selected Phase 3 dose of 5.8 mg/kg in platinum-resistant ovarian cancer, with median duration of response of 12.2 months and median PFS of 11.1 months. GSK has initiated five global Phase 3 pivotal trials in 2026. The drug also received Breakthrough Therapy Designation from China's NMPA in May 2025. For a large-cap pharma like GSK, this is a promising but early-stage pipeline asset with no near-term binary catalyst.

How It Works

An antibody-drug conjugate (ADC), a precision cancer therapy that works like a guided missile. One part of the drug (the antibody) locks onto a protein called B7-H4 found on the surface of ovarian and endometrial cancer cells. Once attached, the cancer cell pulls the drug inside, where a chemotherapy payload (a topoisomerase 1 inhibitor called rezetecan) is released to kill the cell. The design aims to deliver the chemotherapy directly to tumors while sparing healthy tissue.

Trial Status

Phase 1b BEHOLD-1 trial completed enrollment and reported updated data at ESMO 2026 (October 2026) with 62% ORR in PROC and 67% in endometrial cancer. Five global Phase 3 pivotal trials (BEHOLD-Ovarian01, BEHOLD-Endometrial01, and others) began enrolling patients in 2026. A Phase 1/2 BEHOLD-2 combination study is also ongoing.

The Two-Sided Case

▲ Bull Case4
Phase 1b BEHOLD-1 data showed a 62% confirmed objective response rate at the selected Phase 3 dose (5.8 mg/kg) in platinum-resistant ovarian cancer, with median duration of response of 12.2 months and median PFS of 11.1 months, strong for a difficult-to-treat population.
GSK has rapidly advanced the asset into five global Phase 3 pivotal trials in 2026 (BEHOLD-Ovarian01, BEHOLD-Endometrial01, and others), signaling internal confidence.
B7-H4 is widely expressed in ovarian and endometrial cancers but low in normal tissues, offering a differentiated target; >95% of evaluable tumors in BEHOLD-1 were B7-H4-positive.
Received Breakthrough Therapy Designation from China's NMPA in May 2025 for platinum-resistant recurrent ovarian cancer, potentially accelerating the path in a major market.
▼ Bear Case4
Phase 3 trials have only begun enrolling in 2026; pivotal readouts are years away and could fail to replicate Phase 1 response rates.
Competition is intensifying: BeiGene's BG-C9074, another B7-H4-targeted ADC, has also entered Phase 3 for ovarian cancer, and Pfizer's PF-07260437 (B7-H4 bispecific) is in Phase 1.
GSK is a large-cap pharma (~$50B market cap) with dozens of marketed products; even a successful launch would be a modest contributor to overall revenue for years.
The drug is licensed from Hansoh Pharma with an $85M upfront payment plus milestones and royalties, limiting GSK's full upside capture.

Upcoming Catalysts

  • Phase 3 interim/final data readouts from BEHOLD-Ovarian01 (NCT07286266) and BEHOLD-Endometrial01 (NCT07286331), likely 2-3+ years out
  • Potential regulatory submissions in China following NMPA Breakthrough Therapy Designation (timeline unclear)
  • Additional data from BEHOLD-2 combination study

Source Filing

The SecBot filing or press-release report that triggered this drug report:

GSK plc 6-K GSK ·Originating report

Sources · 12

Hover a chip for the title
1 us.gsk.com2 gsk.com3 gsk.com4 onclive.com5 ascopost.com6 pharmaphorum.com7 fiercebiotech.com8 gsk.com9 hspharm.com10 clinicaltrials.gov11 clinicaltrials.gov12 stocktitan.net